The Translational Psychiatry Program is focused on research investigating neurobiology of psychiatric disorders, potential biomarkers and novel therapeutic candidates for such disorders. The research interests include: mania, bipolar disorder, depression and schizophrenia, which present the validities necessary to represent behavioral, neurochemical and pharmacological approaches, similar to alterations found in humans.
The Translational Psychiatry Program is engaged in preclinical and clinical research in the field of psychiatry. The research activities involve in vivo animal models and in vitro models with cell culture developed to investigate the pathophysiology as well as therapeutic targets in psychiatric disorders. The program also conducts clinical studies for biomarkers in bipolar disorder.
- Investigation of biomarkers across psychiatry disease. This project investigates biomarkers in psychiatric disease,
especially bipolar disorder, major depression disorder and schizophrenia.
- Investigation of the neurobiology of psychiatry disorders. The major aim of this research is to examine the pathophysiology as well as search new therapeutic targets to psychiatric disorders.
- Development of human induced-pluripotent stem cells and subsequent differentiation into neuronal cells and astrocytes. Our researchers are developing neuronal cells and astrocytes to obtain virtual brain biopsies of individuals with psychiatric disorders, and understand the mechanisms underlying cellular alterations in mental illness.
- Understanding the role of NLRP-3 inflammasome in bipolar disorder patients. This research investigates the role of NLRP-3 inflammasome in bipolar disorder patients and if the molecular variation in microglia cells from BD might be reflected in iMG cells.
- Relationship between stress and immune activation in the development of depression – an early maternal care deprivation model. We aim to test the hypothesis that an early-life stressful event, such as the maternal care deprivation, causes a pro-inflammatory status that may influence the response to inflammatory challenges during infant and adult life, further contributing to behavioral alterations in adult life.
- Understanding of the molecular events that contribute to microglial activation using antipsychotic drugs to understand the molecular events that contributes to the microglial activation on bipolar, antipsychotic, NMDA receptor antagonist, antidepressant, KYN pathway inhibitor drugs.
Faculty & Postdocs
Joao L. de Quevedo, M.D., Ph.D.
Vice Chair of Faculty
Development & Outreach
Director, Translational Psychiatry
Mood Disorders Program
Consuelo Walss-Bass, Ph.D.
Director, The UTHealth Brain
Collection for Research
in Psychiatric Disorders
Tatiana Barichello, Ph.D.
Gabriel R. Fries, Ph.D.
Antonio L. Teixeira, M.D.,
- Giselli Scaini, Ph.D., Postdoctoral Research Fellow
- Laura Stertz, Ph.D., Postdoctoral Research Fellow
- Vijayasree V. Giridharan, MPharm, Ph.D., Postdoctoral Research Fellow
- Gabriela Delevati Colpo, Ph.D., Postdoctoral Research Fellow
- Natalia Pessoa Rocha, Ph.D., Postdoctoral Research Fellow
Behavioral and Biomedical Sciences Building (BBSB)
1941 East Road
Houston, TX 77054